Results 51 to 60 of about 14,294,829 (187)

Retrospective Analysis of Pemetrexed-based Chemotherapy Regimens on Mid-elderly Non-Hodgkin's Lymphoma

Zhongliu Fangzhi Yanjiu, 2020
Objective To analyze the safety and efficacy of pemetrexed-based chemotherapy on patients with mid-elderly non-Hodgkin's lymphoma. Methods We retrospectively reviewed the clinical data of patients with non-Hodgkin's lymphoma treated with pemetrexed-based
WEN Tingyu, GUI Lin, JIN Jun, ZHANG Wei, WANG Ting, SHI Yuankai, LIU Peng   +6 more
doaj   +1 more source

Mutant NPM1 in Acute Myeloid Leukemia Initiation and Maintenance

Aging and Cancer, Volume 7, Issue 3, Page 109-124, September 2026.
NPM1 mutations drive acute myeloid leukemia by acting as neomorphic transcriptional regulators that cooperate with Menin–MLL and XPO1 to sustain HOX/MEIS1 expression and block differentiation. Targeting these mutant‐specific transcriptional dependencies provides a rational therapeutic strategy for NPM1‐mutated AML.
Yanan Jiang, Zhong Fan, Runmeng Liu, Xiaotian Zhang   +3 more
wiley   +1 more source

Hypercalcemia as a rare presentation of angioimmunoblastic T cell lymphoma: a case report

Journal of Medical Case Reports, 2018
Background Angioimmunoblastic T cell lymphoma is a rare malignancy, accounting for only 2% of all non-Hodgkin lymphomas, first described in the 1970s and subsequently accepted as a distinct entity in the current World Health Organization classification ...
Sana Chams, Inaya Hajj Hussein, Skye El Sayegh, Nour Chams, Khalid Zakaria   +4 more
doaj   +1 more source

The first report of colonic involvement of angioimmunoblastic T-cell lymphoma

The Turkish Journal of Gastroenterology, 2020
Cite this article as: Turan İ, Özsan N, Doğanavşargil B, Arslan Davulcu E, Bülbül H. The first report of colonic involvement of angioimmunoblastic T-cell lymphoma. Turk J Gastroenterol 2020; 5: 413-4.
İlker Turan, Nazan Özsan, Başak Doğanavşargil, Eren Arslan Davulcu, Hale Bülbül   +4 more
doaj   +1 more source

Cardiovascular Immune‐Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta‐Summary of Case Reports

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Reports of immune checkpoint inhibitor (ICI) therapy‐associated immune‐related adverse events (irAEs) exhibit considerable heterogeneity, particularly when comparing data from clinical trials and real‐world observational studies. Methods We conducted a systematic review of real‐world observational studies (case reports and series ...
Shea‐Lee Godin, Tyler Kingma, Ashwin Pillai, Obada Kholoki, Agnes S. Kim   +4 more
wiley   +1 more source

Sustained Belinostat‐Induced Metabolic Response and Tolerability in Heavily Pretreated Relapsed/Refractory Angioimmunoblastic T‐Cell Lymphoma: A Case Report

Clinical Case Reports
Angioimmunoblastic T‐cell lymphoma (AITL), a rare and aggressive subtype of peripheral T‐cell lymphoma (PTCL), often demonstrates resistance to standard therapies.
Vassiliki Labropoulou, Evgenia Verigou, Eleni P. Kourea, Maria Liga, Dimitrios Tsokanas, Krisela‐Christina Valera, Alexandros Spyridonidis   +6 more
doaj   +1 more source

CUTANEOUS MANIFESTATIONS OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA

Vestnik Dermatologii i Venerologii, 2018
Background: Angioimmunoblast T-cell lymphoma (AITL) is a rare T-cell lymphoproliferative disease that is accompanied by generalized lymphadenopathy, hepatosplenomegaly, intoxication symptoms and extranodal lesions.
N. G. Chernova, M. N. Sinitsyna, Yu. V. Sidorova, N. P. Soboleva, A. B. Sudarikov, A. M. Kovrigina, V. N. Dvirnyk, E. E. Zvonkov   +7 more
doaj   +1 more source

TET2 as a Context‐Dependent Epigenetic Integrator in Clonal Hematopoiesis, Inflammation, Cancer, and Immunotherapy

Cell Biochemistry and Function, Volume 44, Issue 8, August 2026.
ABSTRACT Ten‐Eleven Translocation 2 (TET2) is an Fe(II)‐ and α‐ketoglutarate‐dependent dioxygenase that initiates active DNA demethylation by oxidizing 5‐methylcytosine (5mC). Beyond this enzymatic role, TET2 links DNA methylation dynamics with chromatin regulation, cellular metabolism, immune‐cell identity, and treatment response in a context ...
XiaoJie Liu, Jiangchen Liu, Liu Feng, Dan Xu, Xianling Wei, Dekuai Tong   +5 more
wiley   +1 more source

Safety and Effectiveness of Denileukin Diftitox‐cxdl in Patients With Relapsed/Refractory Peripheral T‐Cell Lymphoma and Cutaneous T‐Cell Lymphoma: An All‐Case Post‐Marketing Study in Japan

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Introduction Denileukin diftitox (DD)‐cxdl, a fusion protein comprising diphtheria toxin fragments and human interleukin‐2, is a treatment for peripheral T‐cell lymphoma (PTCL) and cutaneous T‐cell lymphoma (CTCL). Previous trials have enrolled a limited number of patients, and there is a need to evaluate DD‐cxdl in a more diverse population ...
Tatsuro Jo, Kota Matsumoto, Mika Ishii, Koji Izutsu   +3 more
wiley   +1 more source

Diagnostic Challenges in Nodal T-Follicular Helper (TFH) Cell Lymphoma

BioMed
Nodal T-follicular helper cell lymphomas comprise a biologically similar but morphologically diverse family of T-cell neoplasms, including angioimmunoblastic T-cell lymphoma, nodal T-follicular helper cell lymphoma, follicular-type, and nodal TFH ...
Neha Seth, Phyu Thin Naing, Pratik Q. Deb   +2 more
doaj   +1 more source